id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-D-1891-0002,FDA,FDA-2014-D-1891,Draft Guidance for Industry on How to Obtain a Letter from FDA Stating that Bioequivalence Study Protocols Contain Safety Protections Comparable to Applicable REMS for RLD,Other,Guidance,2014-12-05T05:00:00Z,2014,12,2014-12-05T05:00:00Z,,2024-11-11T20:55:08Z,,1,0,090000648195ee4c
FDA-2014-D-1891-0001,FDA,FDA-2014-D-1891,"How To Obtain a Letter From the Food and Drug Administration Stating That Bioequivalence Study Protocols Contain Safety Protections
Comparable to Applicable Risk Evaluation and Mitigation Strategies
for Reference Listed Drugs; Draft Guidance for Industry; Availability",Notice,Notice of Availability,2014-12-05T05:00:00Z,2014,12,2014-12-05T05:00:00Z,2015-02-04T04:59:59Z,2020-04-23T19:23:52Z,2014-28540,0,0,090000648195e613